Stock Analysis on Net

Johnson & Johnson (NYSE:JNJ)

Analysis of Revenues

Microsoft Excel

Revenues as Reported

Johnson & Johnson, income statement, revenues

US$ in millions

Microsoft Excel
12 months ended: Dec 29, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Innovative Medicine 56,964 54,759 67,516 66,715 59,625
MedTech 31,857 30,400 27,427 27,060 22,959
Sales to customers 88,821 85,159 94,943 93,775 82,584

Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Item Description The company
Sales to customers Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Johnson & Johnson sales to customers decreased from 2022 to 2023 but then slightly increased from 2023 to 2024.